p21 in Cancer Research

p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor fu...

Full description

Bibliographic Details
Main Authors: Bahar Shamloo, Sinem Usluer
Format: Article
Language:English
Published: MDPI AG 2019-08-01
Series:Cancers
Subjects:
p21
p53
Online Access:https://www.mdpi.com/2072-6694/11/8/1178
id doaj-439192e527494a4aa900aae3f263e9e2
record_format Article
spelling doaj-439192e527494a4aa900aae3f263e9e22020-11-25T02:18:33ZengMDPI AGCancers2072-66942019-08-01118117810.3390/cancers11081178cancers11081178p21 in Cancer ResearchBahar Shamloo0Sinem Usluer1Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USADepartment of Molecular Biology & Biochemistry, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, 8010 Graz, Austriap21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor function of p21 is the most studied aspect of this protein in cancer, the role of p21 in phenotypic plasticity and its oncogenic/anti-apoptotic function, depending on p21 subcellular localization and p53 status, have been under scrutiny recently. Basic science and translational studies use precision gene editing to manipulate p21 itself, and proteins that interact with it; these studies have led to regulatory/functional/drug sensitivity discoveries as well as therapeutic approaches in cancer field. In this review, we will focus on targeting p21 in cancer research and its potential in providing novel therapies.https://www.mdpi.com/2072-6694/11/8/1178p21cancertherapeutic approachp53gene editing
collection DOAJ
language English
format Article
sources DOAJ
author Bahar Shamloo
Sinem Usluer
spellingShingle Bahar Shamloo
Sinem Usluer
p21 in Cancer Research
Cancers
p21
cancer
therapeutic approach
p53
gene editing
author_facet Bahar Shamloo
Sinem Usluer
author_sort Bahar Shamloo
title p21 in Cancer Research
title_short p21 in Cancer Research
title_full p21 in Cancer Research
title_fullStr p21 in Cancer Research
title_full_unstemmed p21 in Cancer Research
title_sort p21 in cancer research
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2019-08-01
description p21 functions as a cell cycle inhibitor and anti-proliferative effector in normal cells, and is dysregulated in some cancers. Earlier observations on p21 knockout models emphasized the role of this protein in cell cycle arrest under the p53 transcription factor activity. Although tumor-suppressor function of p21 is the most studied aspect of this protein in cancer, the role of p21 in phenotypic plasticity and its oncogenic/anti-apoptotic function, depending on p21 subcellular localization and p53 status, have been under scrutiny recently. Basic science and translational studies use precision gene editing to manipulate p21 itself, and proteins that interact with it; these studies have led to regulatory/functional/drug sensitivity discoveries as well as therapeutic approaches in cancer field. In this review, we will focus on targeting p21 in cancer research and its potential in providing novel therapies.
topic p21
cancer
therapeutic approach
p53
gene editing
url https://www.mdpi.com/2072-6694/11/8/1178
work_keys_str_mv AT baharshamloo p21incancerresearch
AT sinemusluer p21incancerresearch
_version_ 1724881380163190784